SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Mutuum Finance (MUTM) continues to advance through its development roadmap as participation around the project expands. Now firmly positioned in Roadmap Phase 2, the Ethereum-based DeFi crypto is ...
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback